Introduction
Hematopoietic stem and progenitor cells (HSPCs) are non-stop travelers throughout the body in both time and space. At the earliest stages of embryogenesis, primitive hematopoiesis is initiated in the extra-embryonic tissues in yolk sac blood islands. 1, 2 The later appearance of definitive HSPCs in the aorta-gonad-mesonephros region raises the question whether cells identified in this region (i) arrive from the yolk sac at the time when the heart begins to beat and initiates blood flow, 3 (ii) are specified in the aortic wall from a local pool of stem cells as a response to blood-flow shearing forces 4 or (iii) are derived from a subpopulation of primitive mesodermal/germ line cells that migrate through the embryo proper on their way to colonize the genital ridges. 5 Later, at the second trimester of gestation, HSPCs accumulate in the fetal liver (FL), which becomes a major hematopoietic organ in the developing embryo. 6 Finally, at the beginning of the third trimester of gestation, HSPCs leave the FL and begin to colonize in the developing bone marrow (BM). 7 This colonization is regulated by a-chemokine stromal-derived factor-1 (SDF-1), a potent chemoattractant for HSPCs, that at this time is expressed by developing stroma in fetal bones, whereas its receptor CXCR4 is expressed on HSPCs. 8 As SDF-1 and CXCR4 knock-out animals exhibit normal FL hematopoiesis, but impaired colonization of BM by HSPCs, the SDF-1-CXCR4 receptor axis is crucial for BM colonization, but not for accumulation of HSPCs in FL. 9 Later on in adult life, a small percentage of HSPCs is continuously released from BM niches into peripheral blood (PB), which may be envisioned as a highway by which HSPCs can relocate between distant stem cell niches to keep the pool of BM stem cells in balance. In addition to HSPCs, some other rare stem cells (for example, mesenchymal stem cells, endothelial progenitor cells and very small embryonic-like stem cells) may also appear in the PB during various stress situations. [10] [11] [12] Thus, stem cells circulating in PB are 'paramedics' involved in immune surveillance (HSPCs) or tissue/organ rejuvenation (mesenchymal stem cells, endothelial progenitor cells and embryonic-like stem cells). Table 1 lists the most important physiological and pathological situations associated with the increase in the number of circulating stem cells in PB. In adult organisms, circulating stem cells (i) show a circadian rhythm in the circulation with the peak occurring early in the morning and the nadir at night, 13 (ii) are mobilized during strenuous exercise, 14 inflammation 10, 15 and tissue/organ injury (for example, heart infarct or stroke) [16] [17] [18] and iii) may increase in number up to 100-fold after the administration of certain drugs. 19, 20 This enforced translocation of HSPCs from BM into PB induced by pharmacological agents (for example, granulocyte colony stimulating factor (G-CSF) or AMD3100), is called 'mobilization' and mobilized PB, is an easily accessible source of HSPCs for hematopoietic transplantation.
Recent data from our laboratory support a concept, whereby mobilization of HSPCs into PB is orchestrated by innate immunity. 19, 21, 22 In this review we will present evidence that during stress situations, innate immunity and its major arms, (i) activation of the complement cascade (CC), (ii) granulocytes, (iii) naturally occurring antibodies (NA-Ig) and (iv) the network of Toll-like receptors (TLRs), orchestrate egress of HSPCs into the PB. Thus, mobilization of stem cells is an evolutionarily conserved mechanism that is part of the immune response/ reaction to inflammation and organ/tissue damage.
Active retention of HSPCs in BM counterbalances the continuous chemotactic activity of plasma
HSPCs reside in BM attached to endosteal and endothelial niches due to active interaction between ligands expressed in the BM microenvironment and receptors present on the surface of HSPCs. 23, 24 The most important ligands are SDF-1 and vascular adhesion molecule-1 (VCAM-1/CD106), which are expressed in hematopoietic niches and interact with their corresponding receptors expressed on HSPCs: the G-proteincoupled seven-transmembrane-spanning receptor CXCR4 and the integrin receptor very late antigen-4 (VLA-4/a 1 b 4 integrin), respectively. In addition, some other adhesion molecules, as SPOTLIGHT well as some growth factor/growth-factor receptor axes, for example, kit ligand-c-kit receptor, have some role in retention of HSPCs in BM. 25 All of these ligand-receptor axes are susceptible to degradation by proteolytic enzymes secreted during mobilization by myeloid cells (for example, granulocytes or monocytes). [26] [27] [28] Evidence from our laboratory and others increasingly supports the observation that, although SDF-1 has an important role in retention of HSPCs in BM, its level in PB during steady-state conditions and even during mobilization cannot explain the egress of HSPCs, which suggests that other factors present in plasma are responsible. 21, 29, 30 In both humans and mice, the SDF-1 level in plasma during mobilization (i) is insignificantly low (o1-2 ng/ml), (ii) does not correlate with mobilizer status and (iii) is below biologically significant levels that show chemotactic activity against HSPCs in in vitro assays. 31 Furthermore, during mobilization induced with AMD3100, a small-molecule SDF-1 antagonist that blocks the CXCR4 receptor, HSPCs are still able to egress into PB, which suggests that egress of these cells does not depend strongly on the plasma SDF-1 level. 21 Similarly, we also noticed in chemotactic assays in vitro that responsiveness of BM-derived HSPCs to plasma is not affected by the presence of AMD3100. 21 The chemotactic activity of plasma, however, was inhibited after active charcoal stripping that absorbs mainly bioactive lipids. 21 We have, therefore, focused on the identification of this/these lipid(s).
Recent work from our laboratory has confirmed that plasma contains a potent chemoattractant for HSPCs, sphingosine-1 phosphate (S1P), 15, 29, 30 that as we demonstrated recently is responsible for egress of HSPCs into PB. 21 This bioactive lipid is transported in plasma by erythrocytes, lipoproteins (for example, high-density lipoprotein) and albumin. 29, 32 As reported, S1P concentration under steady-state conditions in PB is 25 Â higher than in tissue. 29, 32 Thus, HSPCs that reside in BM must be retained by an active energy-consuming process to counterbalance this S1P gradient in plasma, which, by analogy to a gravitational field, could be envisioned as a kind of continuous chemotactic field. On the basis of this, the most critical steps in mobilization will be (i) attenuation of function of the HSPC retention axes in BM (for example, SDF-1-CXCR4 or VCAM-1-VLA4) and (ii) permeabilization of the marrow-blood barrier in BM sinusoids. As the S1P 'chemotactic field' exists in PB, the increase in chemoattractant level in PB would be unnecessary for egress of HSPCs if these cells were efficiently detached from their niches and the sinusoid endothelial barrier permeabilized.
The mechanisms postulated to be involved in release of stem cells from their BM niches into PB are listed in Table 2 . As mentioned above, attenuation of the SDF-1-CXCR4 and VLA-4-VCAM-1 axes has a crucial role in the mobilization process. 23, 24 This attenuation could be achieved by (i) the induction of a proteolytic microenvironment in BM (for example, G-CSF or cyclophosphamide) 27, 45 or (ii) the blockage of CXCR4 or VLA-4 by specific blocking molecules (AMD3100 or BIO4860, respectively). 23, 33, 45 Retention/mobilization of HSPCs in BM has also been postulated to be influenced by neural mediators (dopamine and b2-adrenergic receptors), 38, 39 as well as being modulated by elements of the coagulation cascade (for example, urokinase receptor). 40 In addition, after administration of G-CSF, the level of SDF-1 in BM, which is important for retention of HSPCs, may also be directly downregulated at the mRNA level in osteoblasts that line osteoblastic niches. 27, 37 Furthermore, although the pro-retention function of osteoblasts is widely acknowledged, a role of osteoclasts in egress of HSPCs is still controversial. 34, 35 It is interesting that a new population of BM-residing monocytes (osteomacs) has recently been identified and postulated to regulate retention of stem cells in BM niches. 46 Although as a subset of myeloid cells, osteomacs should express functional C3a and C5a receptors, it will be important to see whether the function of these cells is modulated by CC cleavage fragments.
Why stem cells are mobilized and circulate in PB?
The fact that HSPCs circulate at low levels in PB during steadystate conditions suggests an important physiological function. It has been calculated, for example, that in mice under steadystate conditions, approximately 400 HSPCs circulate at any given moment in the PB to keep the pool of stem cells in balance between BM niches distributed in distant bones located throughout the body.
Furthermore, as recently demonstrated, HSPCs circulating in PB may enter tissues and return back to the PB through the lymphatic system and thoracic duct. 15 Such tissue patrolling is important during infection, when circulating HSPCs (for example, granulocyte monocyte-colony stimulating factor) are recruited to affected peripheral tissues, in which their local proliferation gives rise to granulocytes, macrophages and dendritic cells. 15 The analogous mechanism could be proposed also for other types of circulating BM-derived stem cells (for example, embryonic-like stem cells, mesenchymal stem cells and endothelial progenitor cells) that in steady-state conditions Table 2 Mechanisms involved in egress/mobilization of stem cells
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Mechanisms References
Proteolytic attenuation/small-molecule antagonist blockage of the SDF-1-CXCR4 axis (CXCR7?) 
16-18
Pharmacological mobilization (e.g., G-CSF or AMD3100)
17,19
Abbreviation: G-CSF, granulocyte colony stimulating factor.
Innate immunity and stem cell mobilization MZ Ratajczak et al are involved in turnover of the stem cell pool, tissue/organ rejuvenation and, in emergency situations, regeneration.
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Recent evidence suggests some specificity in mobilization of particular stem cell subtypes, depending on the mobilizing factors employed. 47 
Pharmacological mobilization of HSPCs
Pharmacological mobilization is currently employed in the clinic to obtain HSPCs for hematopoietic transplantation. The reasons for this are two-fold. First, isolation of HSPCs from PB by leucopheresis is the easier and less stressful way to harvest such cells compared with multiple aspirations of BM cavities. Second, mobilized HSPCs engraft faster, 48 which results in accelerated recovery of blood platelets and granulocytes after transplantation. It is unfortunate that nearly 25% of patients, especially those pretreated with chemotherapy, do not respond efficiently to the currently recommended mobilization protocols and are deemed poor mobilizers. Therefore, gaining an understanding of the molecular mechanisms governing the process of HSPC mobilization will help to develop more efficient mobilization strategies.
Many pharmacological agents have been described that induce mobilization of HSPCs. The cytokine G-CSF is currently the most frequently employed clinical drug that, after a few consecutive daily injections, efficiently mobilizes HSPCs. 27, 49, 50 Mobilization could also be induced within hours after administration of certain chemokines (for example, interleukin-8, growth-related oncogene protein-beta (Gro-b) or macrophage inhibitory protein-1a), multiple injection of certain growth factors (for example, Fms-like tyrosine kinase 3, kit ligand or vascular endothelial growth factor), small-molecule antagonists of the CXCR4 receptor (for example, AMD3100 or T139) or a small-molecule antagonist of VLA-4 (BIO4860). [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] To obtain more efficient and faster mobilization, some of these compounds could be administered together (for example, G-CSF with AMD3100 or growth-related oncogene protein-beta with AMD3100). 28, 61 Mobilization could also be achieved by the administration of some types of polysaccharides (for example, zymosan or fucoidans) that in animal models have been demonstrated to efficiently mobilize HSPCs within 1 h after a single injection. 66, 67 Elements of innate immunity involved in stem cell mobilization Evidence from our, [41] [42] [43] [44] 68 and other laboratories 69, 70 indicates that innate immunity orchestrates egress of HSPCs from BM into PB. Innate or natural immunity is inborn and thus naturally present in an organism; it does not require previous sensitization to an antigen. Because it is not stimulated by specific antigens, innate immunity, in contrast to acquired immunity, is generally nonspecific. The major components of innate immunity, such as (i) CC, (ii) granulocytes, (iii) NA-Ig and (iv) the network of TLRs, will be discussed below in the context of the mobilization process.
The role of CC in mobilization of HSPCs
It should not be surprising that mobilization/circulation of stem cells is directed by the CC in an important and evolutionarily conserved regulatory mechanism for sensing and responding to inflammation and organ injury. As the CC is activated in all the situations listed in Table 1 , for example, as a result of (i) inflammation, (ii) release of CC activating factors from damaged tissues or (iii) strenuous exercise as a result of hypoxia, the release of stem cells into circulation could be envisioned as part of CC-mediated immune surveillance and response to inflammation and organ/tissue damage.
Mechanisms that trigger the activation of CC by (i) classical, (ii) lectin and (iii) alternative pathways (Figure 1 ) are the result of (i) tissue hypoxia, (ii) exposure to intact bacteria, fungi and viruses or their degradation products (for example, endotoxin), (iii) display of some damage-associated antigens on injured tissues (for example, neoepitope or phosphatidyloserine), (iv) release of membrane fragments by activated/damaged cells (for example, microparticles or exososmes), (v) the presence of apoptotic bodies, (vi) activation of the coagulation cascade (for example, thrombin and kallikrein may directly activate downstream elements of CC) and (vii) the activity of some proteolytic enzymes (for example, metalloproteinases, neutrophil-derived elastase or cathepsin-G). [71] [72] [73] [74] [75] [76] Overall, the activation of CC during HSPC mobilization was confirmed by (i) Enzyme-linked immunosorbent assay to detect C3a and C5a clevage fragments in plasma, 19 (ii) immunofluorescence showing deposition of iC3b on BM stroma and endothelial cells [41] [42] [43] and (iii) Enzyme-linked immunosorbent assay and histochemical detection of membrane attack complex (MAC) in BM tissue. 21 Work from our laboratory demonstrates that CC activation in BM is triggered by several mobilizing agents, including G-CSF, mobilizing polysaccharides, such as zymosan, 22 as well as AMD3100. 19 During CC activation, several cleavage fragments are released that modulate (for example, C3a, desArg C3a, C5a or desArg C5a anaphylatoxins) 19, 42, 43, 68, 77 or are crucial for the execution of this process (for example, MAC (C5b-C9)). 21 In support of the involvement of CC, Figure 2 shows histochemical detection of MAC deposits in murine BM during mobilization by G-CSF or zymosan.
CC is activated in BM by different yet overlapping mechanisms, depending on the mobilizing agent employed. For example, our data indicate that CC becomes activated in BM after G-CSF-induced mobilization by NA-Ig that bind to the neoepitope, an antigen that becomes exposed in BM tissue damaged, 42 for example, by the G-CSF-induced proteolytic microenvironment. 27, 45 On the other hand, zymosan activates CC by an alternative pathway. Recent evidence demonstrates also that the classical CC pathway may be activated by C-reactive protein that binds to phosphatidyloserine exposed on damaged cell membranes. 78 This again is a result of the proteolytic microenvironment induced in BM by the mobilizing drug. 23, 25, 26 In a non-canonical mechanism, CC may also be activated directly at the C5 level by coagulation-associated proteases, such as thrombin or kallikrein. 79 Finally, CC may by activated by proteolytic enzymes (for example, elastase, cathepsin-G or matrix metalloproteinases) that are released from granulocytes and monocytes after stimulation of these cells by the mobilizing agent (for example, G-CSF or AMD3100). 19 Data from our laboratory indicate that CC cleavage fragments affect the retention/mobilization process differently. 21, 19, 22, 41, 77 That is, although C3 (C3a or desArg C3a) cleavage fragments increase retention of HSPCs in BM, C5 (C5a or desArg C5a) cleavage fragments enhance their egress into PB. This was evidenced in mobilization studies performed in C3-and C5-deficient animals, which revealed that C3-deficient mice are easy mobilizers 41, 44, 77 and C5-deficient mice are poor mobilizers. 22 To explain why C3 mice are easy mobilizers, we demonstrated that C3a and desArg C3a increase responsiveness of HSPCs to the BM SDF-1 gradient, 41 which seems to be crucial for
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Innate immunity and stem cell mobilizationretention of these cells within BM niches. We recently provided a molecular explanation for this intriguing phenomenon on the basis of the observation that actively signaling CXCR4 is associated with lipid rafts. 22, 41 Lipid rafts are membrane domains rich in sphingolipids and cholesterol, which form a lateral assembly in a saturated glycerophospholipid environment. 41 The raft domains are known to serve as moving platforms on the cell surface and are more ordered and resistant to non-ionic detergents than other areas of the membrane. These domains are also good sites for crosstalk between various cellular signaling proteins. For example, it has been recently reported that small guanine nucleotide triphosphatases (GTPases), such as Rac-1 and Rac-2, which are crucial for the engraftment of hematopoietic cells after transplantation, are associated with lipid rafts on migrating HSPCs. [80] [81] [82] [83] Accordingly, as the CXCR4 receptor is a lipid raft-associated protein, its signaling ability is enhanced if incorporated into membrane lipid rafts, in which it may better interact with several signaling molecules, including the small GTPase Rac-1.
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This co-localization of CXCR4 and Rac-1 in lipid rafts facilitates GTP binding/activation of Rac-1.
We reported that both CC cleavage fragments, C3a and desArg C3a, similar to some cationic peptides released from the activated granulocytes (for example, b2-defensin or cathelicidin), promote incorporation of CXCR4 into membrane lipid rafts and increase responsiveness of HSPCs to SDF-1 homing signals in BM. 22, 41, 42 Thus, generation of C3 cleavage fragments in the BM microenvironment may somehow act as a last line of defense to increase responsiveness of HSPCs to the SDF-1 retention gradient, and thus counteract uncontrolled egress of these cells into the PB. In C3-deficient mice this phenomenon is attenuated, explaining why these animals are defective in retention of HSPCs in BM and are easy mobilizers. 41, 44, 77 Furthermore, we have observed a similar effect after C3aR blockage by employing SB 285944, which is a small-molecule antagonist of this receptor. 77, 44 Thus, modulation of the C3a-C3aR axis may become an important strategy for increasing mobilization of HSPCs in poor mobilizers. 44 By contrast, data in C5-deficient mice demonstrate that activation of the distal part of the CC at the C5 level and generation of C5b-C9 (MAC) is crucial for egress of HSPCs. 21 As we will discuss below, C5 cleavage fragments (C5a and desArg C5a) are crucial mediators for (i) activating BM-residing myeloid cells (precursors of granulocytes/monocytes) to secrete proteolytic enzymes that attenuate homing interactions between HSPCs and their BM niches (for example, SDF-1-CXCR4 or VCAM-1-VLA4 axes), as well as (ii) chemoattracting granulocytes into PB. 22 We hypothesize that granulocytes permeabilize the endothelial barrier in BM sinusoids and thus facilitate subsequent egress of HSPCs. 22, 68 Finally, activation of CC by all pathwaysFclassical, alternative and non-canonicalFgenerates the C5b-C9 MAC, that as we recently demonstrated, is crucial for the release of S1P from erythrocytes. 21 As mentioned above, under steady-state Figure 1 Complement cascade becomes activated in BM during mobilization. The CC may become activated by the classical (NA-Ig-C1 q-triggered), lectin-mannose and alternative (factor B-and D-triggered) pathways. Activation occurs by initiating a cascade of proteolytic reactions, in which one protein is cleaved and acquires proteolytic activity that activates the next downstream protein in the cascade. All of these pathways merge at C3 complement protein, the most abundant CC protein in PB (1 mg/ml). Activation of C3 leads to release of C3a anaphylatoxin. In the next step, C5 is enzymatically cleaved and releases another anaphylatoxin, C5a. Both anaphylatoxins, C3a and C5a, have a short half-life in PB and are immediately converted to desArg C3a and desArg C5a, which have different biological functions. Although C3 cleavage fragments (C3a and desArg C3a) enhance responsiveness of HSPCs to the BM SDF-1 gradient, activation of C5 promotes mobilization of HSPCs by increasing degranulation of granulocytes and facilitating their egress from BM. Thus, we propose that an activated C cascade can affect stem cell mobilization in a negative (C3) or a positive (C5) way shown in blue and red, respectively. The final step of CC activation is creation of the C5b-C9 MAC. During activation, MAC can be inserted into the cell membrane of the target cell or remain outside the cell as soluble MAC (sMAC). CC becomes activated in BM after G-CSF-induced mobilization by the classical, NA-Ig-dependent pathway and after zymosan-induced mobilization due to activation of an alternative pathway. Some alternative mechanisms exist, whereby C5 could be activated and cleaved by proteolytic activity of thrombin and kallikrein, as well as proteases released form activated myeloid cells. The data on the role of the lectin pathway in mobilization of HSPCs are still missing.
conditions, S1P present in PB is a major chemottractant for BM-residing HSPCs and its concentration and PB gradient increase during mobilization (Figure 3) . It is interesting that, we noticed that S1P loses this activity against HSPCs already mobilized into PB. This could be explained by desensitization of S1P binding receptors during the mobilization process.
Furthermore, S1P released from erythrocytes by CC, as well as C5a and desArg C5a cleavage fragments (anaphylatoxins) may also directly increase permeability and leakage of the endothelial cells in BM sinusoids and, by this means, additionally facilitate mobilization. In support of this notion, endothelial cells are known to express both C5a-and S1P-binding receptors.
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Involvement of granulocytes in mobilization
It is well known that granulocytes are required for HSPC mobilization. This is based on the observations that (i) granulocytes are the first cells to egress from BM during mobilization, as reported by others and by us, 22 and (ii) the mobilization process is severely impaired in animals that lack granulocytes 69 . Thus, granulocytes have an important role at several steps of mobilization ( Figure 3 ) and CC cleavage fragments (C5a and desArg C5a) orchestrate this process directly by activating these cells in BM and chemoattracting them into the PB. 22, 68 Accordingly, activated granulocytes release proteolytic enzymes into the BM microenvironment that perturb the SDF-1-CXCR4, VLA-4-VCAM-1 and kit ligand-c-kit receptor homing signals between HSPCs and their niches. 25, 45 Although this is a critical step, the overall role of proteases in HSPC mobilization remains somewhat controversial. It is surprising that mice that are genetically deficient in the expression of several proteases implicated in mobilization of HSPCs mobilize normally. 86, 87 It has been postulated that either the activation of BM-proteases is not required or redundant protease pathways compensate during mobilization in protease knock-out mice. 87 On the other hand, what is intriguing about several mobilizing protocols and what we mentioned above is that granulocytes are described as the first cells to egress from the BM. 60, 61, 69 We hypothesize that in doing so, granulocytes facilitate subsequent egress of HSPCs, which follow 'in their footsteps'. 22 In support of this postulated 'ice-breaker' role of granulocytes in mobilization, several agents employed to induce this process, such as interleukin-8 or growth-related oncogene protein-beta, are primarily strong activators and chemoattractants for granulocytes and may induce their egress from BM. 88 This proposed mechanism, whereby granulocytes permeabilize the sinusoid endothelial barrier, is supported by our recent transmission electron microscopy studies. 22 Furthermore, the role of granulocytes in the egress of stem cells into PB is also supported by the occurrence of granulocytosis, which is rapidly induced by CC during infection or organ damage and precedes egress of stem cells (for example, heart infarct). 89, 90 All these phenomena are directly regulated by C5a anaphylatoxin, which binds to the G-protein-coupled, seven-transmembrane-spanning C5aR present on granulocytic cells and myeloid precursors. 22 At the same time our preliminary data suggest that another C5a/ desArg C5a-binding receptor C5L2 is not involved in the mobilization process.
The role of NA-Ig in mobilization
As mentioned above, activation of the classical CC pathway is initiated by NA-Igs. These pre-existing, low-affinity, germlineencoded antibodies to biologically conserved neo-epitopes recognize these antigens if they become exposed in damaged tissues (for example, on BM cells owing to a proteolytic microenvironment induced after G-CSF administration). The lack of NA-Igs is seen, for example, in immunodeficient patients 91 or immunodeficient mice, 43 which accounts for these individuals being poor G-CSF mobilizers 43 . In support of this, we reported that the poor mobilization in immunodeficient recombination activating gene 2 (RAG2) and severe combined immunodeficient mice (lacking B lymphocytes that develop into immunoglobulin-producing plasma cells) and Jh mice (selectively Ig-deficient) was reversed after supplementation by wild-type Ig before mobilization. 43 Whether a similar strategy Innate immunity and stem cell mobilization MZ Ratajczak et al could be employed in severe combined immunodeficient patients that are poor G-CSF mobilizers 91 requires further study. As mentioned above, some of the mobilizing agents (for example, the polysaccharide zymosan) activate CC by employing an alternative pathway. As this mechanism of CC activation does not require NA-Ig, RAG2-, severe combined immunodeficient-and Jh-immunoglobulin deficient mice, which are poor G-CSF-induced mobilizers, mobilize normally in response to this agent. 43 This also indicates that innate immunity modulates mobilization of HSPCs differently based on the mobilizing agent employed. Overall, this supports the notion that several overlapping/compensatory mechanisms exist to ensure proper functioning of this evolutionarily conserved biological phenomenon.
The involvement of TLRs in mobilization
In addition to CC, granulocytes and NA-Ig, studies in mice have revealed that mobilization is somehow facilitated or directed by the activation of TLRs expressed on BM myeloid cells in response to endotoxin/lipopolysaccharide released by intestinal aneorobic bacteria. 92 This result is based on the observation that when mice are depleted of lipopolysaccharide-producing bacteria, they become poor mobilizers. 92 Thus, TLRs, which regulate several aspects of innate immunity and were recently also found on the surface of HSPCs (in addition to the surface of leukocytes), become important players in modulating the mobilization process. In support of this notion, TLR2 binds zymosan and TLR4 binds lipopolysaccharide. 93, 94 However, the involvement of TLRs in stem cell mobilization requires further study.
Conclusions and future directions
We postulate that retention of HSPCs in BM is an active process that counterbalances an S1P chemoattracting gradient continuously present in PB. 21 Our data support the concept that mobilization of stem cells is part of a more general immune alarm reaction in response to infection and/or tissue and organ damage that releases granulocytes, HSPCs, mesenchymal stem cells, endothelial progenitor cells and embryonic-like stem cells. We postulate that all these circulating/tissue patrolling stem cells have important roles in the immune surveillance and protection of damaged organs. [10] [11] [12] 15 On the basis of this, we propose that modulation of the CC could be an important tool to regulate the release of stem cells from their niches. We have already identified several components of innate immunity (such as C3 and C5 cleavage fragments) that directly or indirectly modulate egress of these cells. 22 For example, the C3aR antagonist SB 285944 has been shown to be effective in enhancing mobilization of HSPCs in an animal model. 44 Furthermore, what has not been addressed in this review is our recent data indicating that innate immunity has a role, not only in mobilization, but also in homing and engraftment of HSPCs after transplantation. 41, 95 Thus, modulation of CC in the BM environment may optimize both mobilization, as well as homing of HSPCs after transplantation. These observations should stimulate the development of new therapeutic approaches.
Finally, future studies will address whether the efficiency of CC activation differs between good and poor mobilizers and determine the effect of CC on the integrity of the osteoblastic Step I: a mobilizing agent (e.g., G-CSF) expands the number of myeloid cells in BM (granulocytes and monocytes) and/or activates them to secrete several proteolytic enzymes that impair homing/retention signals of HSPCs in the BM microenvironment (e.g., SDF-1-CXCR4, VLA-1-VCAM-1 or kit ligand-c-kitR). Activation of secretion of proteolytic enzymes is potentiated by C5 cleavage fragments (C5a, desArg C5a) that directly stimulate granulocytes.
Step II: Granulocytes are usually the first cells that egress from the BM and pave the way for HSPCs that follow their path across the endothelial barrier ('ice-breaker effect'). It is known that C5 cleavage fragments generated in blood due to CC activation are strong chemoattractants for granulocytes and monocytic cells.
Step III: sMAC generated in the final step of CC activation enhances release of S1P from erythrocytes into the plasma and the plasma S1P level potentiates egress of HSPCs into PB. Our data indicate that the plasma SDF-1 level is low, explaining why SDF-1 does not have a major role in chemoattracting HSPCs into blood. niche 37 and eicosanoid level in BM. 96, 97 We envision that CC cleavage fragments (for example, C3a and C5a) may directly regulate the function of osteomacs 36, 46 and the activity of enzymes involved in eicosanoid metabolism (for example, cyclooxygenase-2).
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